Types of immune-inflammatory responses as a reflection of cell–cell interactions under conditions of tissue regeneration and tumor growth


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription Access

Abstract

Inflammatory infiltration of tumor stroma is an integral reflection of reactions that develop in response to any damage to tumor cells including immune responses to antigens or necrosis caused by vascular disorders. In this review, we use the term “immune-inflammatory response” (IIR) that allows us to give an integral assessment of the cellular composition of the tumor microenvironment. Two main types of IIRs are discussed: type 1 and 2 T-helper reactions (Th1 and Th2), as well as their inducers: immunosuppressive responses and reactions mediated by Th22 and Th17 lymphocytes and capable of modifying the main types of IIRs. Cellular and molecular manifestations of each IIR type are analyzed and their general characteristics and roles in tissue regeneration and tumor growth are presented. Since inflammatory responses in a tumor can also be initiated by innate immunity mechanisms, special attention is given to inflammation based on them. We emphasize that processes accompanying tissue regeneration are prototypes of processes underlying cancer progression, and these processes have the same cellular and molecular substrates. We focus on evidence that tumor progression is mainly contributed by processes specific for the second phase of “wound healing” that are based on the Th2-type IIR. We emphasize that the effect of various types of immune and stroma cells on tumor progression is determined by the ability of the cells and their cytokines to promote or prevent the development of Th1- or Th2-type of IIR. Finally, we supposed that the nonspecific influence on the tumor caused by the cytokine context of the Th1- or Th2-type microenvironment should play a decisive role for suppression or stimulation of tumor growth and metastasis.

About the authors

L. A. Tashireva

Cancer Research Institute

Email: d_evgeniy@oncology.tomsk.ru
Russian Federation, Tomsk, 634050

V. M. Perelmuter

Cancer Research Institute

Email: d_evgeniy@oncology.tomsk.ru
Russian Federation, Tomsk, 634050

V. N. Manskikh

Lomonosov Moscow State University

Email: d_evgeniy@oncology.tomsk.ru
Russian Federation, Moscow, 119991

E. V. Denisov

Cancer Research Institute

Author for correspondence.
Email: d_evgeniy@oncology.tomsk.ru
Russian Federation, Tomsk, 634050

O. E. Savelieva

Cancer Research Institute

Email: d_evgeniy@oncology.tomsk.ru
Russian Federation, Tomsk, 634050

E. V. Kaygorodova

Cancer Research Institute

Email: d_evgeniy@oncology.tomsk.ru
Russian Federation, Tomsk, 634050

M. V. Zavyalova

Cancer Research Institute; Siberian State Medical University

Email: d_evgeniy@oncology.tomsk.ru
Russian Federation, Tomsk, 634050; Tomsk, 634050


Copyright (c) 2017 Pleiades Publishing, Ltd.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies